Merck finishes animal vaccine plant overhaul

Merck ($MRK) has completed its expansion and renovation of an Elkhorn, NE, animal vaccine plant and will begin transferring researchers from its Delaware site to the newly improved facility. The company has spent $13.5 million renovating the plant, adding a high-speed vaccine vial filling line and disinfection chambers. Story

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.